Cover Story
FreeGuest Editorial
By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Cancer History ProjectFree
By Alexandria Carolan and Katie Goldberg
Trending Stories
- Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?
- Jeffrey Weber on his career, mentors: “Never ever ever ever blow your cool.”
- NCI-designated Basic Laboratory Cancer Centers get research done—efficiently
- ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck - Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72